28.49
Precedente Chiudi:
$29.46
Aprire:
$29.46
Volume 24 ore:
873.15K
Relative Volume:
0.99
Capitalizzazione di mercato:
$2.19B
Reddito:
$13.17M
Utile/perdita netta:
$-199.06M
Rapporto P/E:
-10.40
EPS:
-2.74
Flusso di cassa netto:
$-156.53M
1 W Prestazione:
-6.47%
1M Prestazione:
-24.71%
6M Prestazione:
-33.97%
1 anno Prestazione:
-26.21%
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Confronta XENE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
XENE
Xenon Pharmaceuticals Inc
|
28.49 | 2.34B | 13.17M | -199.06M | -156.53M | -2.74 |
![]()
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
2025-02-11 | Iniziato | Deutsche Bank | Buy |
2024-10-10 | Ripresa | Raymond James | Outperform |
2024-10-01 | Iniziato | H.C. Wainwright | Buy |
2024-01-04 | Iniziato | Citigroup | Buy |
2023-12-08 | Iniziato | Robert W. Baird | Outperform |
2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
2022-12-14 | Iniziato | Goldman | Buy |
2022-12-12 | Iniziato | Cowen | Outperform |
2022-11-28 | Iniziato | Wells Fargo | Overweight |
2022-10-19 | Iniziato | Raymond James | Outperform |
2022-08-29 | Iniziato | BofA Securities | Buy |
2022-07-21 | Iniziato | JP Morgan | Overweight |
2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
2020-10-02 | Iniziato | SVB Leerink | Outperform |
2020-07-21 | Iniziato | Needham | Buy |
2020-06-01 | Ripresa | Jefferies | Buy |
2020-03-25 | Iniziato | Wedbush | Outperform |
2020-01-08 | Iniziato | William Blair | Outperform |
2019-09-20 | Iniziato | Guggenheim | Buy |
2018-08-08 | Reiterato | Stifel | Buy |
2017-03-13 | Iniziato | Jefferies | Buy |
2016-10-21 | Iniziato | Stifel | Buy |
2016-09-26 | Iniziato | Guggenheim | Buy |
2016-04-14 | Reiterato | Jefferies | Buy |
2015-10-30 | Ripresa | Jefferies | Buy |
2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - Defense World
Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
(XENE) Investment Analysis and Advice - news.stocktradersdaily.com
Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Xenon Pharmaceuticals’ SWOT analysis: neurological drug stock faces pivotal year - Investing.com India
Analysts Issue Forecasts for XENE FY2025 Earnings - Defense World
Leerink Partnrs Has Bullish Forecast for XENE Q2 Earnings - Defense World
XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World
What is William Blair’s Estimate for XENE FY2025 Earnings? - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Evercore ISI - Defense World
HC Wainwright Issues Optimistic Outlook for XENE Earnings - Defense World
How To Trade (XENE) - news.stocktradersdaily.com
Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Chardan Capital Reiterates “Buy” Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Needham & Company LLC Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00 - Defense World
Wells Fargo & Company Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Upgraded by StockNews.com - Defense World
Evercore ISI Group Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform Recommendation - Nasdaq
Xenon signals Phase 3 epilepsy readout in early 2026 with expanded pipeline advancements - MSN
Xenon Pharmaceuticals to Present at 2025 RBC Healthcare Conference - TipRanks
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times
Xenon CEO to Showcase Revolutionary Late-Stage Epilepsy Treatment: Key Updates Coming at RBC Conference - Stock Titan
XENE: Evercore ISI Group Initiates Coverage with 'Outperform' Ra - GuruFocus
XENE: Evercore ISI Group Initiates Coverage with 'Outperform' Rating | XENE Stock News - GuruFocus
Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday - Insider Monkey
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2025 Earnings Call Transcript - Insider Monkey
XENE: Wells Fargo Adjusts Price Target for Xenon Pharmaceuticals - GuruFocus
Xenon Pharmaceuticals (XENE) Price Target Adjusted by Analyst | - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down After Analyst Downgrade - Defense World
XENE: HC Wainwright Reiterates Buy Rating for Xenon Pharmaceuticals | XENE Stock News - GuruFocus
XENE: RBC Capital Adjusts Price Target as Xenon Pharmaceuticals Faces Timeline Shift | XENE Stock News - GuruFocus
XENE: Analyst Reaffirms Buy Rating with Price Target of $55 | XE - GuruFocus
XENE Price Target Revised Following Earnings and Data Delay | XE - GuruFocus
XENE: Needham Adjusts Price Target on Xenon Pharmaceuticals | XE - GuruFocus
XENE: RBC Capital Lowers Xenon Pharmaceuticals Price Target | XE - GuruFocus
FOS-tering patience: Xenon moves azetukalner data to next year - BioWorld MedTech
Xenon Pharmaceuticals stock falls on delayed study results By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals stock falls on delayed study results - Investing.com Australia
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlight - GuruFocus
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position and Promising Clinical Developments - GuruFocus
Xenon Pharmaceuticals Advances Clinical Programs Amid Financial Loss - TipRanks
Xenon Pharmaceuticals Reports Q1 2025 Results and Advances Clinical Pipeline - TipRanks
XENE: Xenon Advances Phase 3 Programs in Epilepsy and Psychiatry | XENE Stock News - GuruFocus
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings: EPS Loss of $0.83 Beats Estimate, Revenue Soars to $7.5 Million - GuruFocus
XENON PHARMACEUTICALS Earnings Results: $XENE Reports Quarterly Earnings - Nasdaq
Xenon Pharmaceuticals: Q1 Earnings Snapshot - San Antonio Express-News
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xenon Pharmaceuticals Inc Azioni (XENE) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Option Exercise |
17.76 |
22,468 |
399,032 |
53,770 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Option Exercise |
17.76 |
16,315 |
289,754 |
46,468 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Option Exercise |
17.76 |
16,217 |
288,014 |
47,519 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Sale |
40.20 |
22,468 |
903,214 |
31,302 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Sale |
40.50 |
16,315 |
660,806 |
31,302 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Sale |
40.08 |
16,217 |
649,977 |
31,302 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):